These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 9272113)

  • 21. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
    Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of 6-aminonicotinamide on the pentose phosphate pathway: 31P NMR and tumor growth delay studies.
    Koutcher JA; Alfieri AA; Matei C; Meyer KL; Street JC; Martin DS
    Magn Reson Med; 1996 Dec; 36(6):887-92. PubMed ID: 8946354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
    Casper ES; Vale K; Williams LJ; Martin DS; Young CW
    Cancer Res; 1983 May; 43(5):2324-9. PubMed ID: 6831457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of high-protein diet on pyrimidine synthesis and response to PALA in mouse tissues.
    Zaharevitz DW; Grubb MF; Hyman R; Chisena C; Cysyk RL
    J Natl Cancer Inst; 1993 Apr; 85(8):662-6. PubMed ID: 8468725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
    Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
    Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
    Chan TC; Markman M; Cleary S; Howell SB
    Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
    van Laar JA; Durrani FA; Rustum YM
    Cancer Res; 1993 Apr; 53(7):1560-4. PubMed ID: 8453623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Five-chlorodeoxycytidine and biomodulators of its metabolism result in fifty to eighty percent cures of advanced EMT-6 tumors when used with fractionated radiation.
    Greer S; Schwade J; Marion HS
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):1059-69. PubMed ID: 7607927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Ardalan B; Jayaram HN; Johnson RK
    Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unexpected synergy between N-phosphonacetyl-L-aspartate and cytidine against human tumor cells.
    Chan TC; Howell SB
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):721-7. PubMed ID: 2714348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin.
    Budihardjo II; Walker DL; Svingen PA; Buckwalter CA; Desnoyers S; Eckdahl S; Shah GM; Poirier GG; Reid JM; Ames MM; Kaufmann SH
    Clin Cancer Res; 1998 Jan; 4(1):117-30. PubMed ID: 9516960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On the relationship of ATP depletion to chemotherapeutically-induced tumor-regression.
    Colofiore J; Stolfi R; Nord L; Martin D
    Int J Oncol; 1995 Dec; 7(6):1401-4. PubMed ID: 21552979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
    Johnson RK; Inouye T; Goldin A; Stark GR
    Cancer Res; 1976 Aug; 36(8):2720-5. PubMed ID: 1064466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic effect reflected by plasma levels of a viral protein during combination chemotherapeutic treatment of mammary tumor-bearing mice.
    Ritzi EM; Martin DS; Stolfi RL; Spiegelman S
    Cancer Res; 1985 Nov; 45(11 Pt 1):5374-8. PubMed ID: 3840411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
    Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pilot study of PALA and 5-FU in patients with advanced cancer.
    O'Connell MJ; Powis G; Rubin J; Moertel CG
    Cancer Treat Rep; 1982 Jan; 66(1):77-80. PubMed ID: 7053270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytological effects of sulfur and selenium purine analogues on two transplantable hepatomas and on normal renewing cells in mice.
    Melvin JB; Haight TH; Leduc EH
    Cancer Res; 1984 Jul; 44(7):2794-8. PubMed ID: 6722809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
    Chan TC; Howell SB
    Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of PALA on the pharmacokinetics of 5-fluorouracil.
    Nassim MA; Rouini MR; Cripps MC; Shirazi FH; Veerasinghan S; Molepo JM; Obrocea M; Redmond D; Bates S; Fry D; Stewart DJ; Goel R
    Oncol Rep; 1998; 5(1):217-21. PubMed ID: 9458325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I evaluation of a biochemically designed combination: PALA, thymidine, and 5-FU.
    Casper ES; Michaelson RA; Kemeny N; Martin DS; Young CW
    Cancer Treat Rep; 1984 Mar; 68(3):539-41. PubMed ID: 6704982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.